Design Therapeutics
DSGN
93 hedge funds and large institutions have $124M invested in Design Therapeutics in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 37 reducing their positions, and 14 closing their positions.
45% more capital invested
Capital invested by funds: $85.5M → $124M (+$38.4M)
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
6% more funds holding
Funds holding: 88 → 93 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.21% less ownership
Funds ownership: 57.61% → 54.39% (-3.2%)
43% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 37
78% less call options, than puts
Call options by funds: $4K | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.59M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$771K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$595K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$572K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$433K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.56M |
| 2 |
Morgan Stanley
New York
|
-$1.63M |
| 3 |
Goldman Sachs
New York
|
-$1.38M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$742K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$596K |
DSGN Hedge Fund Activity: Q1 2024 in Review
93 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2024, worth a combined $124M — up 45% from $85.5M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DSGN positions and 14 closed out — a net gain of 5 holders — while 21 added to existing stakes and 37 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.59M. The largest seller was Citadel Advisors, cutting an estimated $2.56M.
- 93 institutional investors held Design Therapeutics (DSGN) as of Q1 2024, up from 88 in Q4 2023.
- Funds reported $124M of Design Therapeutics stock for Q1 2024, up 45% quarter-over-quarter.
- 19 funds opened new Design Therapeutics positions in Q1 2024 and 14 closed out, a net change of +5 holders.
- The largest Design Therapeutics buyer in Q1 2024 was Point72 Asset Management, an estimated $1.59M added.
- The largest Design Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $2.56M sold.
Based on aggregated 13F filings for Q1 2024.